Table 4 Effect of PTPN22, CTLA-4, and PADI-4 genotypes and the risk of RA in NHS, NHSII and pooled Caucasian matched pairs

PTPN22 ^d

Dominant

CC

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

CT/TT

1.59 (0.96–2.64)

1.10 (0.62–1.96)

8.77 (1.11–69.51)

1.47 (1.05–2.05)

1.46 (1.02–2.08)

0.14

CTLA-4

Dominant

AA

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

AG/GG

1.92 (1.10–3.35)

0.61 (0.32–1.15)

2.18 (0.65–7.38)

1.12 (0.79–1.58)

1.27 (0.88–1.84)

0.02

Additive

AA

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

AG

1.98 (1.09–3.59)

0.52 (0.26–1.04)

2.43 (0.68–8.67)

1.09 (0.76–1.58)

1.24 (0.84–1.84)

0.01

GG

1.85 (1.00–3.41)

0.82 (0.38–1.77)

1.71 (0.40–7.31)

1.15 (0.78–1.70)

1.31 (0.86–1.99)

0.26

Recessive

AA/AG

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

GG

1.13 (0.74–1.74)

1.31 (0.73–2.37)

0.89 (0.30–2.63)

1.08 (0.81–1.44)

1.12 (0.83–1.52)

0.82

PADI-4

Dominant

GG

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

GA/AA

1.10 (0.71–1.71)

1.13 (0.69–1.86)

0.48 (0.15–1.58)

1.02 (0.77–1.35)

1.04 (0.77–1.40)

0.41

Additive

GG

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

GA

1.11 (0.70–1.75)

0.89 (0.51–1.55)

0.19 (0.04–1.03)

0.97 (0.72–1.32)

0.96 (0.70–1.33)

0.14

AA

1.07 (0.56–2.05)

1.72 (0.88–3.36)

1.07 (0.23–4.89)

1.14 (0.77–1.68)

1.24 (0.82–1.89)

0.58

Recessive

GG/GA

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

AA

1.00 (0.56–1.77)

1.82 (0.98–3.38)

1.51 (0.38–5.96)

1.16 (0.81–1.65)

1.27 (0.87–1.86)

0.37